Journal
ONCOGENE
Volume 28, Issue 37, Pages 3286-3295Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.187
Keywords
targeted gene therapy; lung cancer; BiKDD; VISA; survivin
Funding
- NRPGM [DOH97-TD-G-111-041]
- MDACC SPORE [P20 CA101936, 1P50 CA116199, DOH97-TD-111-TM003]
- National Health Research Institutes, Taiwan [PD9602]
Ask authors/readers for more resources
Lung cancer is a leading cause of cancer death due to the high incidence of metastasis; therefore, novel and effective treatments are urgently needed. A current strategy is cancer-specific targeted gene therapy. Although many identified that cancer-specific promoters are highly specific, they tend to have low activity compared with the ubiquitous cytomegalovirus (CMV) promoter, limiting their application. We developed a targeted gene therapy expression system for lung cancer that is highly specific with strong activity. Our expression vector uses the survivin promoter, highly expressed in many cancers but not normal adult tissues. We enhanced the survivin promoter activity comparable to the CMV promoter in lung cancer cell lines using an established platform technology, whereas the survivin promoter remained weak in normal cells. In mouse models, the transgene was specifically expressed in the lung tumor tissue, compared with the CMV promoter that was expressed in both normal and tumor tissues. In addition, the therapeutic gene BikDD, a mutant form of pro-apoptotic Bcl2 interacting killer, induced cell killing in vitro, and inhibited cell growth and prolonged mouse survival in vivo. Importantly, there was virtually no toxicity when BikDD was expressed with our expression system. Thus, the current report provides a therapeutic efficacy and safe strategy worthy of development in clinical trials treating lung cancer. Oncogene (2009) 28, 3286-3295; doi:10.1038/onc.2009.187; published online 13 July 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available